Group 1 - Beijing Huakan Biotechnology Co., Ltd. has successfully completed a B+ round financing of several hundred million yuan, attracting multiple leading investment institutions [1] - The funds from this round will be used to enhance the technical research and development of the cell production system, expand the product matrix, and upgrade the overall solution for large-scale amplification covering the entire lifecycle of cell drugs [1][2] - The company has developed a "3D cell intelligent manufacturing platform" that enables large-scale, automated, and intelligent production of cell drugs, achieving cell preparation in the range of tens of billions to hundreds of billions in a single batch [2] Group 2 - Huakan Biotechnology has established a nearly 7,000 square meter research and transformation platform and a 6,000 square meter GMP production platform, including a 3D FloTrix® cell technology platform [2] - The company has assisted multiple global clients in completing clinical research approval applications for stem cell new drugs, contributing to the approval of China's first stem cell drug [2] - The company is actively implementing a "technology going abroad, industry win-win" strategy, establishing substantial cooperation with clients in over 20 countries and regions across Asia, Europe, and North America [3]
华龛生物完成数亿元B+轮融资 开启细胞产业化发展2.0时代
Zheng Quan Ri Bao Wang·2025-09-15 08:47